European Primary Care Cardiovascular Society
EPCCS 2019 Read impressions of the updates on stroke prevention in AF, hypertension, HF and CV risk in diabetes, with emphasis on challenges faced in patients with multimorbidities.
Profs. McManus and Hobbs consider the latest recommendations and insights on how to diagnose elevated blood pressure and when to initiate treatment.
EPCCS 2019 Dr. Rodrigues zooms in on an individual patient case to illustrate the complexity of management of patients with multimorbidity and polypharmacy.
Among US adults, higher consumption of dietary cholesterol or eggs was significantly associated with higher risk of incident CVD and all-cause mortality in a dose-response manner.
EPCCS 2019 Read an impression of the presentation of prof. Van der Meer, on the latest recommendations on management of HF, including important aspects to consider in patients with comorbidities.
EPCCS 2019 Prof. Hobbs set the scene for the presentation of prof. Khunti, by showing how diabetes is linked to CVD risk, after which prof. Khunti outlined how this risk can best be reduced with therapy.
EPCCS 2019 In a comprehensive talk, professor Hobbs considered a range of aspects relevant to the management of patients with atrial fibrillation (AF), the most common cardiac arrhythmia. Read an impression
EPCCS 2019 In case-based discussions, various complexities of management of patients with multimorbity and polypharmacy were discussed, and strategies to deal with this were exchanged.
Prior to the Annual CV Summit, country representatives of the EPCCS Council gathered in Lisbon to discuss the next necessary steps to expand our European network of GP’s.
ACC 2019 The randomized INFINITY trial showed a reduction in accrual of subcortical white matter disease in older people treated to 130 vs. 145 mmHg, but that did not improve mobility and cognitive function.
ACC 2019 Results of the CLEAR Wisdom trial showed that bempedoic acid lowered LDL-c in high CV risk patients with elevated LDL-c levels who are on maximally tolerated statin and/or other lipid-modifying therapies.
ACC 2019 Dr. Khera explains how the guideline writing committee aimed to compose a comprehensive document to cover all facets of prevention. He discusses some recommendations, including a clear message on aspirin.
